Clinical trialPhase 1Not yet recruiting
Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer
A Phase I, Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of XNW28012 Monotherapy in the Treatment of Subjects With Metastatic Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- 30 July 2026
- Expected end
- 30 April 2028
- Enrollment
- 24 participants
- Sites
- 8
- Primary outcomes
- Incidence of Adverse Events (AEs); Incidence of Serious Adverse Events (SAEs)
- Sponsor
- Industry
- Results posted
- No
- Last update
- 22 July 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try